Benzinga | Aug 20, 2020 07:51AM EDT

Cantor Fitzgerald Maintains Neutral on Momenta Pharmaceuticals, Raises Price Target to $52.5

Cantor Fitzgerald maintains Momenta Pharmaceuticals (NASDAQ:MNTA) with a Neutral and raises the price target from $38 to $52.5.